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Hepatitis B Antigen in V.D. Clinic
Patients
SIR,-Mr. T. H. Bloomfield (30 June, p.
779) challenges the validity of using blood
donors in comparative studies of the inci-
dence of hepatitis b antigenaemnia. The ob-
jection is that the exclusion of potential
donors with a history of jaundice or of re-
cent contract with a case of jaundice may
reduce the proportion of subjects positive
for hepatitis B antigen (HBAg) among
those accepted for donation below the level
in the general population. This contention
is not necessarily correct.
Many of the rejected donors will have
been exposed to the infective agent of viral
hepatitis type A. In general, acute viral
hepatitis type B is not followed by the per-
sistence of HBAg in the serum, and there
have been reports of almost identical
carrier rates in adults with and without a
past history of hepatitis.' Studies2 of hepatitis
B infection among volunteers and those
naturally infected with the virus suggest
that a greater proportion of individuals who
have had a mild or inavarent infection
than of those who have had a more severe
illness become chronic carriers of BHAg.
A series of 5,640 volunteers with a his-
tory of either jaundice or of contact in the
past six months with a case of jaundice have
been tested for HBAg and hepatitis B anti-
body (HBAb). Four were HBAg positive and
three HBAb positive, giving respective in-
cidences of 1 in 1,410 for HBAg and 1 in
1,880 for HBAb. Using the same immiuno-
electro-osmophoretic technique to test for the
first time 123,102 acceptable donors, 145 (1 in
849) were HBAg positive and 121 (1 in
1,017) were HBAb positive.
These findings by current methods of
testing indicate that within the donor popu-
lation of this region volunteers with a his-
tory of jaundice or of recent contact with a
case of jaundice do not have a higher in-
cidence of positivity for HBAg and BAb
than donors lacking this history. More sen-
sitive methods of testing such as haemnag-
glutination and radioimimunoassay might
reveal a different picture.
However, Mr. Bloomfield draws attention
to an important point. Blood donors are un-
representative of the comnunity as a
whole, particularly in respect of age and
sex. Even within a donor population there
are subgroups with different incidences of
HBAg positivity. For example, men
orisoners have a higher incidence of
BAg positivity than non-institutionalized
men, who in turn have a higher incidence
of antigen than women3.-I am, etc.,
JOHN WALLACE
Glasgow and West of Scotland
Blood Transfusion Service,
Law Hospital,
Carluke, Lanarkshire
I Cos,art, Y. E., British Medical Bulletin, 1972, 28.
156.
2 World Health Organization. Viral Hepatitis. Tech-
nical Report Series, No. 512. London, H.M.S.O.,
1973.
3 Wallace, J., Milne, G. R.. and Barr, A., British
Medical 7ournal, 1972, 1, 663.
Confidendplity
SIR,-The recent tape-recorded discussion
on confidentiality and access to large
amounts of data of a highly personal
character (23 June, p. 700) and the sub-
sequent correspondence have focused par-
ticularly on one issue-danger of recorded
data being divulged-but left out almost
entirely another aspect that seems to me
no less important. The computer specialist,
Mr. Barry Barber, who took part in your
discussion came close to stating it when he
said: "The key questions remain: (a) who
may see what part of what record? (b) who
may add to the record? (c) who may alter
the record?"
What is recorded in medical data banks
is not necessarily all, or even part, of what
the subject of the record wished to be re-
corded. It is professional interpretation of
that and of other assessments made by
members of a profession-one of the oldest
professions, it is true, but none the less in-
terpretation of facts or believed facts.
Wit,h the rapid extension of nation-wide
or even more comprehensive data banks
facts are recorded also about credit-wortihi-
ness, alleged crimes, reliability, and all man-
ner of personal information, by members
of professions or quasi-professions who put
down data they consider relevant, leaving
out others, and often adding to them per-
sonal evaluations. Such information may
then remain on the record for as long as the
subject is alive, or even longer.
My point is that the general uneasiness
about computer-aided information process-
ing has given rise to a demand that the sub-
ject himself should have access to all that is
recorded about him, question what he dis-
likes, and, if he so desires, have it removed
from the record.
I am not at all convinced that what ap-
plies to, say, fiscal, criminal, or insurance
records-where all medical doctors would
no doubt agree-should not apply also to
medical records. The possibility of dual
loyalties, even among employed medical
practitioners, is in fact alluded to in your
discussion. It might be argued that a
client, a tax payer, or an alleged criminal
offender can assess a record but that a
patient can not. It might be argued also
that subniarginal illiterate subjects would
not understand the records or that seeing
records might, in exceptional circumstances,
aggravate the subject's condition.
It seems to me (as one concerned with
studies bordering medicine and biology)
that statutory or constitutional safeguards
need to be provided, giving the individual
person the right of access to all informa-
tion stored about himself in data banks,
and to have records altered. If this seems
far-fetdhed in regard to medicine, look per-
ha-ps at the literally vital implications of
psychosomatic "health" or "normality"
under some Orwellian systems of govern-
ment. We like to assume that data are re-
corded and seen only by reasonable in-
dividuals exclusively concerned with the
subject's wellbeing and fair treatment. That
may be so in some countries today. Can
you guarantee that it will be so next year?
-T am, etc.,
H. A. RHEE
Gene a
Hazards of Laparoscopy
Sm,-I would like to comment on the ex-
cellent letters from Drs. M. McD. Usher-
wood and A. D. R. Ogborn (30 June, p.
773) and draw attention to certain relevant
points.
It is wise to teach that all laparoscopic
instruments require careful maintenance.
They are not "nurse-pjroof," and every work-
ing part of each instrument should be
checked at the beginning of each laparo-
scopy by the operator. I am surprised that
Dr. Usherwood was unable to remove the
detached part of his diathermy forceps, as
foreign bodies in the pelvis and abdomen
are usually removed readily at laparoscopy.
I would recommend direct insertion of a
long pair of artery forceps if there is diiffi-
culty in catching and holding a foreign
body with either Palmer's forceps or Step-
toe's grasping forceps.'
As regards the safety of introduction of
the pneumoperitoneum needle to which Dr.
Ogborn draws attention, it is well known
that there are various sites which can be
selected according to the obesity of the
patient and the presence of abdominal scars.'
However, the most important factor in safety
is the actual technique of introduction of
the needle. This should include two definite
steps: (1) the insertion of the Verres or
Palmer needle through the skin into the
subdermal adipose layer of the abdominal
wall only, using two hands on the needle,
one at the cuff and one near the point; (2)
the lifting up of the abdominal wall below
the umbilicus, so that the needle can be ad-
vanced from the fatty layer through the fascia
and peritoneum in a nearly horizontal direc-
tion. Adoption of this technique avoids al-
together the hazard of danaging any retro-
peritoneal structure. The thinner the patient,
the more horizontal should be the final
thrust. Under no circumstances should the
pneumoperitoneum needle be introduced
with the gas source already attached and
flowing, as I have seen some laparoscopists
doing. The risk of puncturing a vessel of
the abdominal wall, no matter which site
is selected, is ever present, so that gas em-
bolism could be caused.
The success of all techniques of laparo-
scopy depends not only on the skill of the
operator, but also on good anaesthesia with
relaxation of the abdominal wall, good in-
strunentation including maintenance, and
constant attention to many minute details
on the part of the laparoscopist. Gynaeco-
logical endoscopy is crying out for the
establishment of special teaching centres so
that the techniques of these most valuable
procedures can be properly taught. Only in
this way can fatalities be avoided.-I am,
etc.,
PATRICK STEPTOE
Oldham and District General Hospital,Oldham, Lancs.
I Stentoe, P. C., Yournal of Reproductive Medicine,
1973, 10, 221.
Toxicity of Benorylate
SIR,-The letter from Professor V. Wright
and Dr. I. Haslock (26 May, p. 487) suc-
cinctly explains that the apparent increase
in the overall incidence of tinnitus in
patients receiving benorylate is most
probably an indication that such patients
are achieving therapeutic plasma salicylate
levels for the first time. However, this logi-
cal explanation does not adequately
explain the unexpectedly high concenta-
tions of plasma salicylate in nine patients re-
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ceiving 2.0 g of benorylate three times a
day, which observations were the subject
of my previous letter (14 April, p. 118).
Further measurements of plasma salicy-
late levels have been undertaken in the
same nine patients and 12 randomly selec-
ted patients with active rheumatoid dis-
ease of the classic form. All patients were
allocated seven days' treatment on benory-
late 4 0 g (10 ml) twice daily followed by a
further seven days during which soluble
aspirin 1-2 g four times a day was sub-
stituted for benorylate. Venous blood was
drawn at 8 am. and at four-hour intervals
thereafter until 8 p.m. Total and free sali-
cylate concentrations were measured in the
separated plasma. Free, unbound, salicylate
was separated by membrane ultrafiltration
utilizing Centriflo ultrafilters.1
The mean total and free salicylate con-
centrations in the plasma of the nine
patients who developed salicylism with
benorylate are shown in the accompany-
ing figure, which records the measurements
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Mean plasma salicylate levels (± S.E.M.) at
4-hourly intervals, achieved with benorylate 4g
twice daily with soluble aspirin 1-2 g four times a
day in nine patients with rheumatoid arthritis.
obtained on the third day of each regimen.
In these patients plasma total salicylate
concentrations were greater while they were
taking benorylate than when taking soluble
aspirin, the differences being statistically
significant at 8 a.m. (P = 0-02) and 8
p.m. (P < 001). Free salicylate concentra-
tions followed the same pattern except that
the levels following benorylate were highly
significantly greater than during aspirin
administration at each sampling time
(P < 0-001). When taking aspirin the re-
lationship between plasma free and total
salicylate concentrations was in keeping
with data obtained in other studies.2 How-
ever, during benorylate administration the
concentration of free salicylate recorded
was markedly greater than would be ex-
pected at the total plasma salicylate con-
centrations which were observed. Since
toxicity rather than clinical effectiveness
is associated with free salicylate concentra-
tions greater than 0 6 mmol/ 1. in most
individuals,3 then it would seem that the
increased incidence of salicylism in these
nine patients, when on benorylate, as com-
pared with aspirin treatment, is a reflection
of the unexpectedly greater concentrations
of unbound salicylate in their plasma during
benorylate administration.
Considering the 12 other patients in-
cluded in the study, the incidence of sali-
cylism was the same on both treatment
regimens, one patient developing the symp-
toms while receiving aspirin and one while
taking benorylate. There were no signifi-
cant differences between the plasma sali-
cylate levels achieved when receiving ben-
ory:ate and those obtained while taking as-
pirin, the mean values being 1-64 mmol/ 1.
at 8 a.m. and 1-68 mmol/ 1. at 8 p.m.
while taking aspirin, and 1-72 mmol/l. at
8 a.m. and 1-78 mmol/l. at 8 p.m. when
taking benorylate. T-hese plasma levels are
similar to those achieved by Robertson et
al.4 when giving benorylate to normal vol-
unteers.
Coomparison of the two groups of patients
revealed no significant differences in age,
sex ratio, duration and severity of the dis-
ease process, or previous drug histories.
Furthermore, there was no consistent quan-
titative differences between the plasma con-
centrations of albumin, alpha- and beta-
globulins or IgM, IgA, and IgG. However,
an in vitro study of the binding characteris-
tics of the plasma of patients in the study
indicated a difference between the two
groups in that in the plasma of the patients
who developed salicylism on benorylate the
ratio of proteinbound to free salicylate was
mo-dified by the presence of benorylate at
a concentration of 10 ,ug/ml. This modifica-
tion manifested as a greater concentration
of free sa'icylate at each total salicylate con-
centration than was obtained in the absence
of the benorylate molecule. This phenom-
enon was not observed in plasma from
those patients who showed tolerance of
benorylate at the recommended dosages.
These results suggest that in certain in-
dividuals the benorylate molecule might
interfere with the binding of salicylate to
plasma proteins, but they do not explain
the higher total salicylate concentrations
which were observed while the patients
were taking benorylate.-I am, etc.,
MANSEL AYLWARD
Research Division,
Merthyr General Hospital,
Merthyr Tydfil, Glam
Blatt, W. F., Robinson, S. M., and Bixler, H. J.,Analytical Biochemistry, 1968, 26, 151.
2 Davison, C., and Smith, P. K., Yournal of Phar-
macology and Experimental Therapeutics, 1961,133, 161.
3 Smith, M. J. H., and Dawkins, P. D., Yournal of
Pharmacy and Pharmacology, 1971, 23, 729.Robertson, A., Glynn, J. P., and Watson, A. K.,
Xenobiotica, 1972, 2, 339.
Fenfluramine and Growth
Hormone Release
SIR,-Dr. D. L. F. Dunleavy and others (7
July, p. 48) describes increased nocturnal
growth hormone secretion in a patient
while on fenfluramine. An intenmittent
sampling method has the advantage of
studying growth hormone secretion under
conditions as near as possible to those un-
der which fenfluramine is commonly used.
Their findings might therefore have more
clinical relevance than those of Mr. W. R.
Sulaiman and Dr. R. H. Johnson (12 May,
p. 329).
We, too, have studied overnight growth
hormone secretion in a patient before and
during treatment with fenfluramine, but by
a continuous sampling method, estimating
growth hormone in hourly coilections. The
patient was a 14-year-old girl weighing 95
kg. Overnight growth hormone secretiop was
studied on admission to hospital. She was
then started on treatment with fenflura-
mine 40 mg twice daily and a further over-
night study was carried out 48 hours later.
Before and during the studies she was not
dieting and lost no weight. Plasma fenflura-
mine levels during the second night of
study were 144.2 ng/ml at 21-30 hours and
97-2 ng/ml at 06-00 hours. Growth hor-
mone secretion for the two nights is shown
in the figure. The result is inconclusive, but
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certainly does not suggest increased growth
hormone secretion when the girl was on fen-
fluramine. This is in contrast to the finding
in Dr. Dunleavy's patient. We cannot ac-
count for this. However, Dr. Dunleavy and
his colleagues do not mention whether
there was any weight change in their
patient between the two studies. Growth
hormone secretion may be diminished in
the obese patient, returning to more nor-
mal levels with weight reduction.'
The confusion in reports on the effect of
fenfluramine on growth hormone levels2 3
may only creflect the many independent
pathways regulating secretion. It seems
possible that different tests of growth hor-
mone secretion may test the integrity of
different pathways.4 A drug acting on the
central nervous system might stimulate
some pathways and depress others, so that
the recorded effect might depend on the par-
ticular test used. However, this would not
explain the discrepancy between our re-
sult and that of Dr. Dunleavy and his col-
leagues. There is need for further study.
It remains questionable whether any
change in growth hormone secretion in the
patient on fenfluramine is of clinical impor-
tance. Growth hormone secretion and
growth rate correlate only poorly. Without
clinical evidence that fenfluramine does not
depress growth rate-which may be diffi-
cult to demonstrate-paediatricians may be
slightly concerned that they are causing
